Davis TE - Search Results

1

Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.

Earhart RH, Amato DJ, Chang AY, Borden EC, Shiraki M, Dowd ME, Comis RL, Davis TE, Smith TJ. Earhart RH, et al. Among authors: davis te. Invest New Drugs. 1990 Feb;8(1):113-9. doi: 10.1007/BF00216936. Invest New Drugs. 1990. PMID: 2188926 Clinical Trial.

2

Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastine.

Earhart RH, Khandekar JD, Faraggi D, Schinella RA, Davis TE. Earhart RH, et al. Among authors: davis te. Invest New Drugs. 1989 Jul;7(2-3):255-60. doi: 10.1007/BF00170870. Invest New Drugs. 1989. PMID: 2793383 Clinical Trial.

3

A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract.

Barrett JT, Orofiamma B, Khandekar JD, Carbone PP, Comis RL, Davis TE. Barrett JT, et al. Among authors: davis te. Cancer. 1989 Dec 15;64(12):2445-7. doi: 10.1002/1097-0142(19891215)64:12<2445::aid-cncr2820641208>3.0.co;2-j. Cancer. 1989. PMID: 2684384 Clinical Trial.

4

Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.

Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, Davis TE, Fazzini E, Cheuvart B, Horton J. Wiernik PH, et al. Among authors: davis te. Cancer Invest. 1992;10(1):1-9. doi: 10.3109/07357909209032783. Cancer Invest. 1992. PMID: 1735009 Clinical Trial.

5

Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion.

Earhart RH, Koeller JM, Davis TE, Borden EC, McGovren JP, Davis HL, Tormey DC. Earhart RH, et al. Among authors: davis te, davis hl. Cancer Treat Rep. 1983 Jul-Aug;67(7-8):683-92. Cancer Treat Rep. 1983. PMID: 6871883

6

A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study.

Trump DL, Marsh JC, Kvols LK, Citrin D, Davis TE, Hahn RG, Vogl SE. Trump DL, et al. Among authors: davis te. Invest New Drugs. 1990;8 Suppl 1:S91-4. doi: 10.1007/BF00171992. Invest New Drugs. 1990. PMID: 2199402

7

Phase II evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer.

Chang AY, Kuebler JP, Tormey DC, Anderson S, Pandya KJ, Borden EC, Davis TE, Trump DL. Chang AY, et al. Among authors: davis te. Cancer. 1986 Jan 1;57(1):54-9. doi: 10.1002/1097-0142(19860101)57:1<54::aid-cncr2820570112>3.0.co;2-d. Cancer. 1986. PMID: 3940622

8

Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion.

Koeller JM, Trump DL, Tutsch KD, Earhart RH, Davis TE, Tormey DC. Koeller JM, et al. Among authors: davis te. Cancer. 1986 Jan 15;57(2):222-5. doi: 10.1002/1097-0142(19860115)57:2<222::aid-cncr2820570206>3.0.co;2-x. Cancer. 1986. PMID: 3510700

9

High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.

Trump DL, Elson PJ, Borden EC, Harris JE, Tuttle RL, Whisnant JK, Oken MM, Carignan JR, Ruckdeschel JC, Davis TE. Trump DL, et al. Among authors: davis te. Cancer Treat Rep. 1987 Feb;71(2):165-9. Cancer Treat Rep. 1987. PMID: 3802113

10

Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma.

Elson PJ, Earhart RH, Kvols LK, Spiegel R, Keller AM, Kies MS, Davis TE, Stevens C, Gumas L, Trump DL. Elson PJ, et al. Among authors: davis te. Cancer Treat Rep. 1987 Mar;71(3):331-2. Cancer Treat Rep. 1987. PMID: 3815401 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

203 results

Search Page

Filters